Cambridge pulmonary hypertension outcomes review (CAMPHOR) utility assessment in pulmonary hypertension (PH) patients

D. Meads, S. McKenna, N. Doughty, J. Pepke-Zaba (Manchester, Cambridge, United Kingdom)

Source: Annual Congress 2007 - Pulmonary hypertension in the clinic
Session: Pulmonary hypertension in the clinic
Session type: Electronic Poster Discussion
Number: 3292
Disease area: Pulmonary vascular diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Meads, S. McKenna, N. Doughty, J. Pepke-Zaba (Manchester, Cambridge, United Kingdom). Cambridge pulmonary hypertension outcomes review (CAMPHOR) utility assessment in pulmonary hypertension (PH) patients. Eur Respir J 2007; 30: Suppl. 51, 3292

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Responsiveness of cambridge pulmonary hypertension outcome review (CAMPHOR) scores and utility in pulmonary hypertension (PH) patients
Source: Eur Respir J 2007; 30: Suppl. 51, 343s
Year: 2007

The CAMbridge pulmonary hypertension outcome review (CAMPHOR): development and validation
Source: Eur Respir J 2004; 24: Suppl. 48, 111s
Year: 2004

An evaluation of outcomes for patients with pulmonary hypertension (PH) incorporated into a standard UK pulmonary rehabilitation (PR) programme
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016


Observational retrospective study on the treatment of pulmonary hypertension (PH) associated to pulmonary disease in patient with PH out of proportion
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013

Clinical characteristics of the pulmonary hypertension (PH) in a cardiologist service
Source: Annual Congress 2011 - Clinical features of pulmonary hypertension
Year: 2011


Smoking history and pulmonary arterial hypertension (PAH) onset and clinical outcomes (REVEAL)
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020


Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension
Year: 2019

HRQoL in adult patients with Eisenmenger syndrome (ES) compared to patients with primary pulmonary hypertension (PPH) or post-embolic pulmonary hypertension (PEPH)
Source: Eur Respir J 2002; 20: Suppl. 38, 455s
Year: 2002

Initial results of the UK audit of chronic thromboembolic pulmonary hypertension (CTEPH)
Source: Eur Respir J 2007; 30: Suppl. 51, 486s
Year: 2007

Pulmonary rehabilitation in patients with group 3 pulmonary hypertension: evaluation of clinical outcomes, adherence and safety.
Source: International Congress 2019 – The future of pulmonary rehabilitation discussed today
Year: 2019


Item performance of the pulmonary arterial hypertension symptoms and impact (PAH-SYMPACT®) questionnaire: Results from the SYMPHONY study with macitentan
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016

Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015


An international survey of current pulmonary arterial hypertension (PAH) management
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012


EmPHasis-10 is associated with clinical outcome measures in pulmonary hypertension
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013


Current epoprostenol use in patients with severe pulmonary hypertension (PH): Data from the French PH registry
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011

Pulmonary hypertension (PH) in chronic obstructive pulmonary disease (COPD): Preliminary data of a longitudinal survey
Source: International Congress 2014 – Clinical presentations
Year: 2014


Risk factors for elevated liver function tests (eLFTs) in patients with pulmonary arterial hypertension (PAH) treated with sitaxentan and followed in a European safety registry
Source: Annual Congress 2011 - Experimental pulmonary hypertension
Year: 2011

Comparison of activities of daily living in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH)
Source: International Congress 2016 – Best abstracts in exercise capacity and testing in chronic lung diseases
Year: 2016


The assessment of life expectancy of patients with primary pulmonary hypertension (PPH)
Source: Eur Respir J 2003; 22: Suppl. 45, 582s
Year: 2003

Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH)
Source: Annual Congress 2010 - Pulmonary circulation II
Year: 2010